|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5200 USD | -5.42% |
|
-9.66% | -68.24% |
| Market Cap | 5.02M 4.4M 4.07M 3.76M 7.12M 481M 7.26M 48.87M 18.99M 235M 18.85M 18.44M 817M | P/E 2026 * |
-4.58x | P/E 2027 * | 1.37x |
|---|---|---|---|---|---|
| Enterprise Value | 5.02M 4.4M 4.07M 3.76M 7.12M 481M 7.26M 48.87M 18.99M 235M 18.85M 18.44M 817M | EV / Sales 2026 * |
0.21x | EV / Sales 2027 * | 0.15x |
| Free-Float |
86.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: NEXGEL, Inc.
| 1 day | -5.42% | ||
| 1 week | -9.66% | ||
| Current month | +2.06% | ||
| 1 month | -7.21% | ||
| 3 months | -19.81% | ||
| 6 months | -69.92% | ||
| Current year | -68.24% |
| 1 week | 0.51 |  | 0.57 |
| 1 month | 0.48 | | 0.69 |
| Current year | 0.48 | | 1.9 |
| 1 year | 0.48 | | 2.89 |
| 3 years | 0.48 | | 5.1 |
| 5 years | 0.48 | | 5.1 |
| 10 years | 0.48 | | 5.1 |
| Manager | Title | Age | Since |
|---|---|---|---|
Adam Levy
CEO | Chief Executive Officer | 63 | 2019-09-09 |
Ian Blackman
DFI | Director of Finance/CFO | 58 | 2026-04-26 |
Gregory J. Robb
COO | Chief Operating Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Jerome Zeldis
BRD | Director/Board Member | 76 | 2020-03-31 |
Kevin Harris
BRD | Director/Board Member | 55 | 2026-05-05 |
| Director/Board Member | 55 | 2025-07-30 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.42% | -9.66% | -80.92% | -77.17% | 5.02M | |
| -0.55% | +2.91% | +57.70% | +170.63% | 1,102B | |
| -0.30% | +4.93% | +71.07% | +67.08% | 643B | |
| -0.40% | +0.95% | +33.56% | +88.45% | 450B | |
| -1.35% | +1.86% | +29.96% | +26.26% | 336B | |
| -0.71% | +0.72% | +28.85% | +46.77% | 288B | |
| -1.31% | -0.26% | -28.18% | -39.13% | 222B | |
| +0.23% | +1.95% | +24.04% | +63.93% | 199B | |
| -0.54% | +7.39% | +21.81% | +78.73% | 169B | |
| +0.69% | +1.53% | -5.37% | -32.05% | 137B | |
| Average | -0.99% | +3.01% | +15.25% | +39.35% | 354.51B | |
| Weighted average by Cap. | -0.58% | +2.07% | +40.69% | +86.37% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 24.06M 21.1M 19.48M 18.01M 34.13M 2.3B 34.81M 234M 91.01M 1.13B 90.36M 88.38M 3.91B | 34.13M 29.94M 27.64M 25.54M 48.41M 3.27B 49.38M 332M 129M 1.6B 128M 125M 5.55B |
| Net income | -976K -856K -790K -730K -1.38M -93.45M -1.41M -9.5M -3.69M -45.73M -3.67M -3.58M -159M | 3.85M 3.38M 3.12M 2.88M 5.46M 369M 5.57M 37.5M 14.57M 180M 14.47M 14.15M 627M |
| Net Debt | - | - |
Employees
19
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-08 | US$0.5113 | -7.00% | 51,926 |
| 26-07-07 | US$0.5498 | +1.78% | 122,169 |
| 26-07-06 | US$0.5402 | -4.32% | 238,995 |
| 26-07-02 | US$0.5646 | -0.25% | 286,213 |
| 26-07-01 | US$0.5660 | +12.97% | 492,573 |
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.5498USD
Average target price
2.000USD
Spread / Average Target
+263.77%
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- NXGL Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
